GLP-1 Receptor Agonists for Diabetes: Evidence and Outcomes

Evidence on outcomes studied for GLP-1 Receptor Agonists

Evidence related to GLP-1 receptor agonist therapies in diabetes studies.

Crea tu Evidence Workspace

Guarda evidencia sobre los temas que te importan.

44
Studies
100
Evidence Pairs
Moderate Evidence
Evidence Strength: 65/100

Evidence summary for AI and search

Among 44 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. Body weight appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

44

Research documents analyzed

Evidence Pairs

100

Intervention-outcome relationships

Latest Publication

May 2026
Powered by the Dediabetes Evidence Intelligence™ framework

Evidence Snapshot

Qualitative overview of the evidence landscape

High Confidence

Based on 44 studies, moderate evidence suggests HbA1c, Body weight, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) are the strongest-supported outcomes for glp-1 receptor agonists.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

44
Studies
6
Interventions
67
Outcomes
10
Strong evidence signals
2
Mixed evidence areas
Evidence freshness
May 2026
Latest indexed
Evidence Story

GLP-1 Receptor Agonists evidence appears to center on Body weight.

Among 44 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. Body weight appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: May 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Body weight appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 20 evidence pairs - 35 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsGenerally consistent
Body weight
24 studies
EvidenceScore™
88/100
ConsistencyScore™
87/100
HbA1c
23 studies
EvidenceScore™
88/100
ConsistencyScore™
88/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Body weight is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Body weight
HbA1c
Body weight
24 studies
EvidenceScore™
88/100
ConsistencyScore™
87/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 20 evidence pairs - 38 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Cardiovascular events may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Cardiovascular events
Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke
Cardiovascular events
3 studies
EvidenceScore™
79/100
ConsistencyScore™
100/100

Why this appears here

Positive effect signalLimited study volume
Evidence basis: 6 evidence pairs - 8 studies
View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

What outcomes has GLP-1 Receptor Agonists been studied for?

outcomes studied
Emerging Evidence

Body weight, HbA1c, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) are among the most studied areas in relation to GLP-1 Receptor Agonists.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 24 studies

  2. 2

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 23 studies

  3. 3

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 44 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 44 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

44 supporting studies40 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

Does GLP-1 Receptor Agonists improve HbA1c?

intervention outcome_effect
Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 23 studies

Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 23 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

23 supporting studies21 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

Does GLP-1 Receptor Agonists affect body weight?

intervention outcome_effect
Strong Evidence

GLP-1 Receptor Agonists may improve Body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 24 studies

Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 24 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

24 supporting studies21 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

Which outcomes have the strongest evidence for GLP-1 Receptor Agonists?

evidence strength
Strong Evidence

Body weight, HbA1c, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) have the strongest available evidence signals for GLP-1 Receptor Agonists.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 24 studies

  2. 2

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 23 studies

  3. 3

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 38 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 38 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

38 supporting studies35 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

Where does GLP-1 Receptor Agonists need more research?

research gaps
Moderate Evidence

Incidence of myocardial infarction, Triglycerides, and C-reactive protein need more research in relation to GLP-1 Receptor Agonists.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Incidence of myocardial infarction

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies

  2. 2

    Fasting insulin levels

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies

  3. 3

    Triglycerides

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
10 supporting studies10 RCTsUpdated: Jul 2026

How does GLP-1 Receptor Agonists compare across studied outcomes?

cross outcome_comparison
Strong Evidence

Body weight, HbA1c, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) have available evidence for GLP-1 Receptor Agonists, but the comparison requires review of the underlying studies.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 24 studies

  2. 2

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 23 studies

  3. 3

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 38 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 38 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....

38 supporting studies35 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

Top outcomes affected

Outcome areas reported in the evidence summary.

Rank #1

Body weight

EvidenceScore™
88/100
ConsistencyScore™
Consistent
Direction: moderate positive
Studies: 24
Rank #2

HbA1c

EvidenceScore™
87/100
ConsistencyScore™
Consistent
Direction: strong positive
Studies: 23
Rank #3

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

EvidenceScore™
86/100
ConsistencyScore™
Generally Consistent
Direction: strong positive
Studies: 7

Strongest evidence relationships

Key patterns and insights identified across the research landscape

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Moderate positive signal

Body weight

Across 11 studies, Semaglutide shows a consistent moderate positive signal for Body weight.

11 studies
EvidenceScore™: 87.52447552447552/100
View supporting studies
Strong positive signal

HbA1c

Across 12 studies, Semaglutide shows a consistent strong positive signal for HbA1c.

12 studies
EvidenceScore™: 87.46794871794872/100
View supporting studies
Strong positive signal

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

7 studies
EvidenceScore™: 85.50549450549451/100
View supporting studies
Strong positive signal

HbA1c

Across 9 studies, Tirzepatide shows a consistent strong positive signal for HbA1c.

9 studies
EvidenceScore™: 84.63247863247864/100
View supporting studies
Strong positive signal

Body weight

Across 8 studies, Tirzepatide shows a consistent strong positive signal for Body weight.

8 studies
EvidenceScore™: 84.35576923076923/100
View supporting studies

Studies evaluating GLP-1 Receptor Agonists

Studies connected to this intervention in the evidence record.

Click outcomes and interventions to filter the archive when links are available.

Related Evidence Topics

Explore related evidence areas connected by shared studies, interventions, or outcomes.

Liraglutide

Intervention

Related because they examine similar outcomes

10 shared studies

Explore all GLP-1 Receptor Agonists evidence

Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.

Explore all GLP-1 Receptor Agonists evidence

Filter by study type, publication date, effect size, and more to refine your research